Athenex

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

[Athenex @AthenexInc]

Today we announced Quantum Leap Healthcare Collaborative reported positive trial result of I-SPY2 Trial for Oral Paclitaxel in combination with PD-1 and Carboplatin in neoadjuvant breast cancer. https://t.co/CqCE35wPwO #Athenex

[Athenex @AthenexInc]

Today, we announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy. https://t.co/aWNo20RC3t #Athenex

[Athenex @AthenexInc]

This week, our team attended the What She's Made Of event @HighmarkStadm. Athenex is a proud supporter of @WNYWomensFndn. To learn more about the organization and event, visit: https://t.co/XuAtbTQmio #WSMO2022 #WomenInSports #GirlsWithGoals #WomenWorthWatching

[Athenex @AthenexInc]

We will be participating in the @jpmorgan Corporate Challenge Buffalo, taking place in Delaware Park on June 16. Join us in this global celebration of camaraderie and teamwork! Athenex’s Buffalo based employees can register online by May 25 6pm ET: https://t.co/wJUD5GOeUb #JPMCC

[Athenex @AthenexInc]

We are devastated and saddened by the tragedy that occurred in our community on May 14, 2022.

[Athenex @AthenexInc]

Today we announced a clinical collaboration with @Merck to evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) https://t.co/mUrgVplTh7 #Athenex

[Athenex @AthenexInc]

Dr. Daniel Lang, President, Athenex Cell Therapy, discusses the advantages of the NKT cell platform over T cell and NK cell-based technologies on the @LifeSciAdvisors Benchtop Bios podcast. Listen here: https://t.co/uFmm8mk7Fe

[Athenex @AthenexInc]

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy @bcmhouston will present Phase 1 clinical data for KUR-501, an autologous GD2 CAR-NKT cell therapy for relapsed/refractory high risk neuroblastoma at #ASGCT22 https://t.co/QAUH5bdVtW @ASGCTherapy

[Athenex @AthenexInc]

We will provide a corporate and financial update for the first quarter 2022 on Tuesday May 10, at 8:00am ET. To join the earnings conference call: https://t.co/uPXlfqj2nJ #Athenex $ATNX

[Athenex @AthenexInc]

Interim data from our Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia, was presented at the 2022 Transplantation & Cellular #Tandem22 Meetings of @ASTCT and @CIBMTR. For more information: https://t.co/pfAueoowO2

[Athenex @AthenexInc]

UPDATED: We will provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday March 16, at 4:30pm ET. To join the earnings conference call: https://t.co/Wuoirv8tNB #Athenex $ATNX

[Athenex @AthenexInc]

Thanks to our colleagues and community for supporting #HospiceSpringBouquetSale & to Athenex coordinator Jessica Gladysz, for making this event possible! Across our #WNY sites, our team raised over $1700 for @hospicebuffalo - almost doubling last yr’s donations! #BouquestinBloom

[Athenex @AthenexInc]

Congratulations to Michael Smolinski, Athenex Chief Scientific Officer, who is featured on the @BfloBizFirst 10th annual #Power250 list! #WNY #Buffalo https://t.co/LKhl0LHQ2s

[Athenex @AthenexInc]

Today, we announced that Mr. Joe Annoni will join Athenex as our new Chief Financial Officer https://t.co/xaZdu1xqVu

[Athenex @AthenexInc]

Today we announced we have entered into a definitive agreement for @ImmunityBio to assume our leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets. For more information, see our press release: https://t.co/plYazIe1Gx #Athenex

[Athenex @AthenexInc]

Join us @LifeSciComms Corporate Access Event Innovative Approaches to #CellTherapy for Oncology panel discussion, where we'll explore the application of cell therapy-based technologies, to address unmet needs in #oncology. The event starts Jan 7 8:30am ET: https://t.co/o3v4nSZT9X

[Athenex @AthenexInc]

Today we will host a KOL webinar on our CAR-NKT technology and discuss the data presented @ASH_hematology #ASH21, where interim results from 5 evaluable patients in the ANCHOR study of KUR-502 showed 80% ORR and 60% CR at lowest dose levels. https://t.co/Wqp8kHsLqa #Athenex

[LifeSci Advisors @LifeSciAdvisors]

Please join us for the @AthenexInc KOL Webinar on Athenex's CAR-NKT Approach featuring presentations by Key Opinion Leaders (KOL's) Dr. Metelitsa, Dr. Ramos, and Dr. Neelapu. A live Q&A session will follow. Register here: https://t.co/L4UUwIJCU5

[Athenex @AthenexInc]

Today we will be presenting a the Evercore ISI 4th Annual HealthCONx Conference at 3:55pm ET. For more information: https://t.co/KbCRzbgeGm #Athenex

[Athenex @AthenexInc]

Today we announced UK MHRA validation of the Marketing Authorization Application for oral paclitaxel and encequidar for review. For more information: https://t.co/2XRCQtvRIK #Athenex